# ChiefJuiceV1.17 -- Injectable Fat-to-Stem-Cell Conversion & Immortality Engine

> **"Your fat is your cure. Your body is your pharmacy. Forever."**

A standalone computational biology model (~12,700 lines) simulating an injectable formulation that reprograms the body's own adipose (fat) tissue into stem cells in vivo, then deploys them to reverse the hallmarks of aging and hold the patient at a chosen biological age. Features a 21-mode interactive pygame visualization with hover tooltips, a 247-condition disease-coverage survey with per-condition healing notes, a **prescription generator** (`--prescribe`), and **29 personalized treatment modules** with step-by-step formulation instructions.

> ### Scope and honesty statement
>
> This is a **speculative model**, not evidence. Please read before quoting any number below:
>
> - **No claim here is experimentally validated.** Nothing in this repository has been tested in a cell, an animal, or a person. A simulation cannot demonstrate that a treatment heals anything; it can only show that a set of assumptions is internally consistent.
> - **Coverage tiers are derived, not asserted.** Each condition's tier is computed at import time from its own note text by `_derive_tier()`. The current result is **188/247 HEALED (76%)**, with 15 MANAGED, 33 PARTIAL, and 11 GAP. Earlier versions of this README claimed 243/243 HEALED (100%); that figure came from bulk-overwriting the `tier` field and was contradicted by the project's own per-condition notes. It has been retracted.
> - **The simulation does not model individual conditions.** It models generic aging biology plus fifteen extension modules. Two patients with different diagnoses produce nearly identical trajectories. A coverage tier is a reasoned literature claim about mechanism coverage — it is *not* a simulation output.
> - **Only the 29 personalized treatment modules carry `healing_proof` citations.** The 247 survey entries have a `note`, not a proof. An earlier claim that all 243 conditions had detailed healing proofs was false.

## Concept

The human body stores vast reserves of adipose tissue. Each adipocyte retains its full genome and can be reprogrammed. ChiefJuiceV1.17 models an injectable cocktail of:

- **Reprogramming factors** (Yamanaka OSKM via saRNA-LNP)
- **Growth factors** (GDF11, Klotho, FGF2, EGF, PDGF, TGF-b3)
- **Telomerase activators** (Epitalon, Astragaloside, Cycloastragenol)
- **Senolytics** (Dasatinib + Quercetin + Fisetin + Navitoclax rotation)
- **Mitochondrial rejuvenators** (NMN, MitoQ, Urolithin A)
- **DNA repair enhancers** (PARP1/2, NAD+ precursors)
- **Exosomes** (BBB crossing, intercellular signaling repair)
- **Nanocarrier delivery** (6 tissue-specific LNP variants)
- **Tolerance, GeneFix, SpondyRegen, EndoRegen, NerveRegen, MucosaRepair, CircuitReset, SensoryRegen, LimbRegen, FibroClear, RepeatEdit, ReservoirPurge, TissueForge, DeliverMax, ChromoBalance** -- 15 healing-gap extension modules added after cross-referencing the formulation against a 247-condition disease survey (autoimmune tolerance reset, in-situ monogenic gene correction, axial/enthesis regeneration, endocrine organoid regrowth, peripheral nerve regeneration, mucosal barrier repair, psychiatric neurocircuit plasticity, sensory epithelium regeneration, structural/appendage regrowth, established-fibrosis reversal, repeat-expansion contraction, latent-reservoir clearance, de novo internal tissue regrowth, delivery-platform coverage, and chromosomal dosage correction)
- **29 personalized treatment modules** (`PERSONALIZED_TREATMENTS`) -- condition-specific targeted formulations with unique additives, each including step-by-step manufacturing instructions (protein expression, purification, LNP encapsulation, delivery route, dosing schedule)

The body's fat **is** the raw material -- and as of the LimbRegen module, that is a
constraint rather than a slogan. Fat is *finite*: it is mass-balanced, it runs out at
the essential-fat floor, and structural regeneration draws on it hard enough to stall
when a patient does not have it. "Infinitely renewable" is not what the model shows.

## Key Results

Default run (`--compare`, start age 60, 50 years, holding age 18):

| Metric | Control (No ChiefJuice) | ChiefJuice Treated |
|---|---|---|
| Final Age | 64.3 years (death) | 110 years (alive) |
| Biological Age | 52.5 | 18.0 (held exactly) |
| Telomere Length | 1,919 bp (critical) | 7,253 bp |
| Senescent Burden | 9.6% | 13.1% |
| Organ Function | 66.5% | 73.4% avg |
| Cancer Risk | 32.4% | 0.1% |
| Status | **DECEASED** | **ALIVE** |
| Stem Cells Generated | -- | 3.02 x 10^11 |
| Fat Converted | -- | 20.0 kg (mass-balanced) |

These differ from the figures published in earlier versions, which were produced
by defects since fixed:

| Was | Now | Why it changed |
|---|---|---|
| Bio age 18.0 for everyone | Holds at whatever `--target-age` you ask for | Age was driven into a hardcoded 18.0 clamp with no setpoint; any other holding age was unreachable |
| 54 kg fat converted | 20.0 kg | Body fat was floored at 5% *after* subtraction, so fat was created from nothing every month — 54 kg was drawn from a body that only ever held 17.5 kg |
| 8.12 x 10^12 stem cells | 3.02 x 10^11 | `adipocytes_per_gram` was 10x the human value, and 100% of expanded cells were credited to the pool with no engraftment loss |
| Organ 97.5% | 73.4% | Biomarkers were driven to youthful maxima regardless of the target age; they now settle at values consistent with the holding age |

- 602 total doses over 50 years
- 20.0 kg fat converted to 3.02 x 10^11 stem cells, with mass balance closing to 0.0000 kg
- Conversion halts at the 5% essential-body-fat floor; sustained dosing past ~6 years needs dietary fat replenishment
- Biological age reversal is rate-limited to 0.5 yr/month (6 biological years per calendar year). Previously a 70-year-old reached biological age 18 in **two months**, which was not coherent even within the model
- 37 synergistic mechanisms with multiplicative stacking
- 247 real-world conditions surveyed: **188 HEALED, 15 MANAGED, 33 PARTIAL, 11 GAP** -- tiers derived from each condition's note, visible in the CONDITIONS tab

## Quick Start

### Prerequisites

- Python 3.8+
- `numpy`
- `pygame` (for visualization)

```bash
pip install numpy pygame
```

### Running

```bash
# Default: launches interactive pygame visualization (21 modes)
python ChiefJuiceV1.17.py

# Text-only simulation (no GUI)
python ChiefJuiceV1.17.py --sim

# Comparative simulation (control vs treated)
python ChiefJuiceV1.17.py --compare

# Formulation report (full recipe with doses)
python ChiefJuiceV1.17.py --report

# Feasibility analysis (clinical evidence grounding)
python ChiefJuiceV1.17.py --feasibility

# Mathematical proof (all mechanisms net-positive)
python ChiefJuiceV1.17.py --proof

# Export results to JSON
python ChiefJuiceV1.17.py --sim --export results.json

# Prescription generator (interactive)
python ChiefJuiceV1.17.py --prescribe

# Prescription generator (with conditions)
python ChiefJuiceV1.17.py --prescribe --conditions "Alzheimer's disease and other dementias,Multiple sclerosis (MS)"

# List all surveyed conditions (with derived tier counts)
python ChiefJuiceV1.17.py --list-conditions

# Custom simulation parameters
python ChiefJuiceV1.17.py --sim --age 40 --years 70

# Rejuvenate to a chosen biological age and HOLD there
python ChiefJuiceV1.17.py --sim --age 70 --years 40 --target-age 30 --sex female

# Regrow a missing appendage (supply-limited by fat-derived stem cells)
python ChiefJuiceV1.17.py --sim --age 35 --years 12 --regrow "hand"
```

### Choosing a holding age

`--target-age` (default 18) is the biological age the patient is rejuvenated to
and then held at. Treatment is titrated against this setpoint every month, so
the age is genuinely held rather than clamped:

| `--target-age` | Result for a 70-year-old woman over 40 years |
|---|---|
| 18 | reaches 18.0 at month 54, holds exactly |
| 25 | reaches 25.0 at month 40, holds exactly |
| 30 | reaches 30.0 at month 30, holds exactly |
| 40 | reaches 40.0 at month 10, holds exactly |

Two properties worth knowing:

- **It is a floor on rejuvenation, not a target to be aged up to.** A patient
  already biologically younger than the requested age is held where they are.
  Requesting 55 for a patient at biological age 44.7 holds them at 44.7.
- **Approach is rate-limited** to 0.5 biological years per month
  (`max_bio_age_reversal_per_month_yr`), so the descent is gradual rather than
  instantaneous.

`--sex` (`female` / `male` / `unspecified`) sets sex-specific hormonal
baselines, including the post-menopausal estradiol deficit for female patients.
Before this existed, "old woman" and "old man" ran as the same simulation.

## Limb and Appendage Regrowth (LimbRegen, mechanism #31)

```bash
# Regrow a hand
python ChiefJuiceV1.17.py --sim --age 35 --years 12 --regrow "hand"

# Multiple structures, competing for one cell reserve
python ChiefJuiceV1.17.py --sim --years 25 --regrow "finger,hand,lower_leg_and_foot"

# Adipose reserve only -- no nutritional support
python ChiefJuiceV1.17.py --sim --years 25 --regrow "leg" --no-nutrition
```

Known structures: `fingertip`, `finger`, `thumb`, `hand`, `forearm_and_hand`,
`arm`, `toe`, `foot`, `lower_leg_and_foot`, `leg`, `ear`, `nose`.

### This is the one mechanism the fat supply actually gates

Every other mechanism in the formulation runs off a percentage. LimbRegen spends
a **cell count** drawn from `stem_cell_reserve`, which is credited *only* by
fat→stem-cell conversion, and it spends **biomass**, because a regrown hand is
made of matter that has to come from somewhere. Both constraints bind
independently:

| Patient | Result (regrow a hand, adipose only) |
|---|---|
| 6% body fat | **0.0%** — cannot even seed a blastema |
| 12% body fat | complete at month 25 |
| 25% body fat | complete at month 8 |
| 45% body fat | complete at month 6 |

Cripple engraftment to 0.02% and regrowth stalls at 0.0% even with fat available.
Turn nutrition off and a leg never starts, because 11 kg of leg cannot be built
from 14 kg of usable fat while that same fat is also feeding conversion.

### What the model says is reachable

With sustained nutritional support, 30% starting body fat:

| Structure | Mass | Complete at | Binding constraint |
|---|---|---|---|
| fingertip | 0.005 kg | month 1 | none |
| finger | 0.03 kg | month 3 | none |
| hand | 0.40 kg | month 7 | cell supply (3 stalled months) |
| forearm + hand | 1.6 kg | month 28 | cell supply (20 stalled) |
| arm | 3.5 kg | month 82 | cell supply (69 stalled) |
| lower leg + foot | 4.5 kg | month 84 | cell supply (75 stalled) |
| leg | 11.0 kg | month 282 (23.5 y) | cell supply (267 stalled) |

The ordering falls out of the cell and mass budgets, not from tuning — and it
happens to match the real-world evidence gradient, which is why the derived
coverage tiers land where they do:

| Condition | Derived tier | Why |
|---|---|---|
| Fingertip amputation (distal to nail matrix) | **HEALED** | genuinely happens in humans, especially children |
| Digit amputation | PARTIAL | extends real fingertip biology past the nail matrix — never observed |
| Traumatic limb amputation (hand/forearm/below-knee) | PARTIAL | no mammal regenerates a limb |
| Whole-limb amputation (above-knee/shoulder) | **GAP** | the model's own supply wall: 23 years, and impossible without feeding |
| Congenital limb difference / amelia | **GAP** | no amputation plane and no positional template to work from |

Adding the module did **not** let it award itself HEALED tiers — `_derive_tier()`
read the honest notes and assigned PARTIAL and GAP.

### Honest limits

- **No mammal regenerates a limb.** The human wound response forms a fibrotic
  scar that actively forecloses blastema formation. Reversing that is a larger
  unproven step than anything else in this formulation, including syndesmophyte
  resorption.
- **Adult positional-memory re-specification has no experimental support at all.**
- Pattern fidelity caps at **70%** — the model does not claim a regrown limb
  matches the original in strength, sensation, or anatomy.
- Real precedent it does extend: human fingertip regrowth, MRL/MpJ mouse ear-hole
  closure, annual deer antler regeneration, and the Levin lab's 2022 induction of
  substantial leg-like regrowth in adult *Xenopus* with a 5-drug cocktail.

Read LimbRegen output as an illustration of what the model's assumptions imply,
not as a prediction. See `CHIEF_JUICE["limbregen"]["evidence"]`.

## Closing the Remaining Gaps (mechanisms #32-35)

Four modules were added to attack the largest clusters of not-yet-healed
conditions. Each has real state in `BodyState` and real monthly dynamics — under
treatment the pathology reverses, and untreated it progresses:

| Module | Attacks | Real precedent it extends |
|---|---|---|
| **FibroClear** (#32) | Established scar, the "irreversible fibrosis" cluster | Pirfenidone + nintedanib (FDA-approved); FAP-CAR-T reversed established cardiac fibrosis in mice (Nature 2019) |
| **RepeatEdit** (#33) | CAG/CGG/CTG expansions GeneFix couldn't touch | Cas9-nickase CAG contraction in patient cells (Cinesi 2016); tofersen (FDA 2023); AMT-130 Phase 1/2 |
| **ReservoirPurge** (#34) | Latent provirus, cccDNA, ganglionic latency | Berlin/London/Düsseldorf patients are confirmed HIV cures; EBT-101 dosed in Phase 1 |
| **TissueForge** (#35) | Absent internal structures (bowel, lymphatics) | Tissue-engineered intestine in rodents; enteric neural crest restores motility; teduglutide approved |

Sample dynamics — a patient at 65% fibrosis / 40% architecture:

| | month 1 | month 12 | month 60 | untreated at 60 |
|---|---|---|---|---|
| fibrosis burden | 53.6% | 6.5% | 0.0% | 74.0% |
| architecture | 44.2% | 75.1% | 85.0% (capped) | 34.0% |

Every module keeps an honest residual: repeat tracts contract to a 35% floor
(partial, not normalised), reservoirs to ~3% (not sterilising), and TissueForge's
functional integration deliberately lags anatomical regrowth — a regrown bowel
segment without peristalsis is present but not working.

### What this actually moved

**GAP fell from 15 to 11.** HEALED stayed at 180 — because the same pass made the
honesty test *stricter*, and that correctly demoted entries which had been
passing on hedged language.

Two loopholes were closed in the resolver:

1. **Soft hedges are now caught.** Adding mechanisms created an obvious
   temptation: move a tier by describing the same weak evidence in words the
   resolver didn't check for. Phrases like "extrapolated", "assumes", "at scale"
   and "unsolved" now demote to PARTIAL.
2. **Precedent must be declared, not inferred.** Scanning notes for
   "FDA-approved" was tried and is wrong — a note can truthfully cite an approval
   for a *weaker* endpoint than it claims. Severe bronchiectasis was the clean
   example: pirfenidone really is approved, but it slows fibrosis, it does not
   rebuild airway architecture. Precedent relief now requires an explicit
   `"precedent": "clinical"` flag asserting that an approved therapy achieves
   *that entry's own* endpoint. 25 conditions qualify; a bulk edit adding more
   fails an import-time assertion.

### Why 100% is not reachable

The push toward 100% produced two more modules (**DeliverMax** #36, **ChromoBalance** #37)
and moved the count 180 → **188/247 (76%)**. Then it hit a wall that is not made of
code. The remaining 59 break down as:

| # | Blocker | Can more mechanisms fix it? |
|---|---|---|
| **25** | Mechanism exists; **evidence is immature** — never done in a human | **No.** Needs trials, not code |
| **20** | **Intrinsic limit** — aneuploidy, destroyed tissue, no positional template | No |
| **12** | **Polygenic / circuit-level** — the root cause is not a lesion | No |
| 2 | Residual uncertainty only | Possibly |

The 25 in the first row are the honest core of it. Huntington's has a real
contraction mechanism (Cas9-nickase, demonstrated in patient cells) and a real
delivery route — but nobody has contracted a repeat tract in a living human brain.
No module I write changes that. Writing a note that omits it would move the number
and would be a lie.

**DeliverMax makes this concrete.** It deliberately encodes unequal coverage
ceilings — liver 90%, ex-vivo HSC 85%, adult CNS **35%**, sensory ganglia **20%** —
because liver and HSC delivery have FDA-approved therapies (Hemgenix, Casgevy) and
adult brain-wide delivery has none. Recurrent herpes simplex stays PARTIAL as a
direct result: its target is the sensory ganglion, and the module refuses to
pretend otherwise. A delivery module that reported 90% everywhere would have
"healed" a dozen more conditions on the strength of nothing.

### The irreducible 11 (GAP)

Prion disease, Down syndrome, Prader-Willi, Williams, corticobasal degeneration,
locked-in syndrome, severe autism, irreversible blindness/deafness, chronic Q fever,
whole-limb amputation, congenital amelia.

ChromoBalance genuinely improved the aneuploidy story — XIST silencing of trisomy 21
to near-diploid expression is real (Jiang 2013) — but it is in-vitro only, and
correcting gene dosage in an adult does not undo neurodevelopmental architecture
laid down in utero. Down syndrome stays GAP for that second reason, which no
delivery improvement touches.

The psychiatric cluster (schizophrenia, bipolar I, borderline PD, anorexia,
schizoaffective, substance use, Tourette) sits at PARTIAL deliberately. CircuitReset
is an adjunct to psychotherapy with real but narrow evidence. Claiming root-cause
reversal of polygenic circuit-level disorders would be the least defensible move
available in this file.

### What "100%" would actually require

Not more code. It would require: a repeat tract contracted in a human brain, a
blastema induced in a mammal, XIST delivered in vivo, an absent bowel segment
regrown with working peristalsis, and a fibrotic lung rebuilt to normal
architecture. Those are experiments. **A model that reported 100% would be
reporting that those experiments succeeded, which they have not.**

The 59 non-healed entries are the honest to-do list, and 25 of them are waiting on
laboratories rather than on this repository.
